SOCRA - Society of Clinical Research Associates Essential Study Documents Questions and Answers

Question 1

A clinical trial protocol is amended to include a new secondary objective and an additional blood draw at Visit 3. According to ICH GCP, which of the following essential documents must be updated, approved by the IRB/IEC, and implemented by the site BEFORE the changes are enacted for any new or existing participants?

Accepted Answer

The signed protocol, the informed consent form, and any other relevant written information for subjects.

Answer

ICH GCP E6(R2) requires that any amendment to the protocol that affects the conduct of the trial or increases risk to subjects must be documented. A change in objectives and procedures necessitates updating the protocol itself and, crucially, the informed consent form (ICF) to ensure subjects are aware of the new procedures and can provide consent. These revised documents must be submitted to and approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) before implementation.

Question 2

On an FDA Form 1572, the Principal Investigator (PI) signs to attest they will personally conduct or supervise the investigation. In Block #6, the PI lists the names of sub-investigators who will assist in the conduct of the trial. Which of the following individuals would typically NOT need to be listed in Block #6?

Accepted Answer

A staff nurse who performs intermittent study assessments, such as vital signs, but does not make significant original contributions to the data.

Answer

FDA guidance on the Form 1572 clarifies that individuals who provide ancillary or intermittent care but do not make a direct and significant contribution to the data do not need to be listed in Block #6. A nurse taking vital signs falls into this category, whereas pharmacists preparing the investigational product and physicians/fellows performing key trial functions like consenting and safety evaluation are considered to have a direct and significant role.

Question 3

Which of the following essential documents is primarily intended to provide the investigator and other site staff with a comprehensive summary of the nonclinical and clinical data on the investigational product accumulated to date?

Accepted Answer

The Investigator's Brochure (IB)

Answer

The Investigator's Brochure (IB) is a compilation of the clinical and nonclinical data on the investigational product(s) that are relevant to the study of the product(s) in human subjects. Its purpose is to provide the investigators and others involved in the trial with the information to facilitate their understanding of the rationale for, and their compliance with, key features of the protocol, such as the dose, dose frequency/interval, methods of administration, and safety monitoring procedures.

Question 4

According to ICH GCP E6(R2) Section 8, essential documents are grouped by their relevance before, during, and after the trial. Which set of documents must be on file at the investigator site BEFORE the clinical phase of the trial commences?

Accepted Answer

Signed protocol, IRB/IEC approval of the protocol and ICF, and the current Investigator's Brochure.

Answer

ICH GCP E6(R2) Section 8.2 outlines the documents that should be on file before the trial's clinical phase begins. This includes documentation of investigator and sponsor agreement to the protocol, IRB/IEC approval for the study documents (protocol, ICF, recruitment materials), and the current Investigator's Brochure to provide scientific information to the investigator.

Question 5

A clinical investigator is participating in a pivotal Phase III drug trial intended to support a marketing application. According to 21 CFR Part 54, the investigator must provide the sponsor with sufficient financial information. The investigator must promptly update this information if any relevant changes occur during the investigation and for what period of time following the completion of the study?

Accepted Answer

For 1 year following study completion.

Answer

According to 21 CFR 54.4(b), the investigator is required to provide the sponsor with accurate financial information and must 'promptly update this information if any relevant changes occur in the course of the investigation or for 1 year following completion of the study.' This ensures that the sponsor has current information when submitting the marketing application to the FDA.

(SOCRA) Society of Clinical Research Associates Practice Test

(SOCRA) Society of Clinical Research Associates Practice Test

SOCRA - Society of Clinical Research Associates Essential Study Documents Questions and Answers